Overview

Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Status:
Recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.

Phase:

Phase 2

Details

Lead Sponsor:

Redx Pharma Plc

Collaborator:

Simbec Research